Literature DB >> 29545033

Is Surgical or Catheter-based Interventions an Option After an Unsuccessful Mitral Clip?

Felix Kreidel1, Hannes Alessandrini2, Peter Wohlmuth3, Michael Schmoeckel4, Stephan Geidel4.   

Abstract

The objective of this study was to assess the results of catheter-based and surgical reinterventions in primary mitral regurgitation after failed MitraClip therapy. We report on 21 consecutive symptomatic patients with primary mitral regurgitation (median age 78 years) who underwent either repeat MitraClip therapy (n = 7) or mitral valve surgery (n = 14) after failure of the index procedure with 1-2 MitraClip implantations. At the time of reinterventions, 193 (interquartile range [IQR]: 32-622) days after the index procedure, patients had recurrent or persistent grade 3 mitral regurgitation. Early mortality at 30 days was 4.8%. Cardiac-related survival at 2 years was 85.4% (4 cardiac and 4 noncardiac deaths). Three of 7 patients with percutaneous reintervention were converted to surgery at 34, 52, and 56 days because repeat MitraClip therapy was ineffective because of pre-existing clip detachment or leaflet tear. Final therapy was biological mitral valve replacement in 14 of 21 patients (66.7%); 4 were treated with percutaneous repeat MitraClip repair (19%), and in 3 patients, surgical repairs were performed (14.3%). At follow-up with a median of 708 days, New York Heart Association class had improved significantly to class 2 (IQR: 1.0-2.5) (P = 0.0004), and the left ventricular end-diastolic diameter had decreased from 56 (IQR: 52-59) mm to 51 (48-58) mm (P = 0.0378), respectively. Recurrence of significant mitral regurgitation was absent in all but 1 patient with unsuccessful repeat MitraClip therapy who was deemed inoperable. Our data show that both repeat MitraClip and also mitral valve surgery are feasible and safe alternatives in patients without an excessively increased perioperative risk. We conclude that whenever leaflet insertion is not compromised, repeat catheter-based repair is a reasonable redo concept; in the remaining cases, surgery should be offered to the patient.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MitraClip; mitral regurgitation; mitral valve; primary mitral valve disease

Mesh:

Year:  2018        PMID: 29545033     DOI: 10.1053/j.semtcvs.2018.03.005

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  5 in total

1.  Electrosurgical Detachment of MitraClips From the Anterior Mitral Leaflet Prior to Transcatheter Mitral Valve Implantation.

Authors:  John C Lisko; Adam B Greenbaum; Robert A Guyton; Norihiko Kamioka; Kendra J Grubb; Patrick T Gleason; Isida Byku; Jose F Condado; Andres Jadue; Gaetano Paone; Peter C Block; Lucia Alvarez; Joe Xie; Jaffar M Khan; Toby Rogers; Robert J Lederman; Vasilis C Babaliaros
Journal:  JACC Cardiovasc Interv       Date:  2020-09-30       Impact factor: 11.195

2.  An updated meta-analysis of MitraClip versus surgery for mitral regurgitation.

Authors:  Nicholas A Oh; Polydoros N Kampaktsis; Michele Gallo; Alvise Guariento; Viktoria Weixler; Steven J Staffa; Dimitrios V Avgerinos; Andrea Colli; Ilias P Doulamis
Journal:  Ann Cardiothorac Surg       Date:  2021-01

3.  Minimally invasive mitral valve replacement after transcatheter edge-to-edge repair.

Authors:  Daniel P Bent; Robert S Boova
Journal:  J Surg Case Rep       Date:  2021-05-27

4.  Re-do MitraClip in patients with functional mitral valve regurgitation and advanced heart failure.

Authors:  Michael M Kreusser; Andreas Weber; Nicolas A Geis; Leonie Grossekettler; Martin J Volz; Sonja Hamed; Hugo A Katus; Sven T Pleger; Norbert Frey; Philip W Raake
Journal:  ESC Heart Fail       Date:  2021-09-08

Review 5.  Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Authors:  Zhang Xiling; Thomas Puehler; Lars Sondergaard; Derk Frank; Hatim Seoudy; Baland Mohammad; Oliver J Müller; Stephanie Sellers; David Meier; Janarthanan Sathananthan; Georg Lutter
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.